PE20150672A1 - Formulaciones de opioides - Google Patents

Formulaciones de opioides

Info

Publication number
PE20150672A1
PE20150672A1 PE2015000092A PE2015000092A PE20150672A1 PE 20150672 A1 PE20150672 A1 PE 20150672A1 PE 2015000092 A PE2015000092 A PE 2015000092A PE 2015000092 A PE2015000092 A PE 2015000092A PE 20150672 A1 PE20150672 A1 PE 20150672A1
Authority
PE
Peru
Prior art keywords
buprenorphine
depot
opioid formulations
salts
opioid
Prior art date
Application number
PE2015000092A
Other languages
English (en)
Inventor
Fredrik Tiberg
Ian Harwigsson
Markus Johnsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53487482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150672(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/558,463 external-priority patent/US20130190341A1/en
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of PE20150672A1 publication Critical patent/PE20150672A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)

Abstract

La invencion describe una formulacion precursora de deposito que comprende: a) una matriz de liberacion controlada; b) al menos solvente organico que contiene oxigeno; c) al menos 12 % en peso de al menos un agente activo que se selecciona de la buprenorfina y sales de esta, calculada como base libre de buprenorfina. Se proporcionan composiciones de deposito y metodos de tratamiento correspondientes en cuanto al manejo del dolor mediante mantenimiento con opioides y metodos relacionados
PE2015000092A 2012-07-26 2013-07-26 Formulaciones de opioides PE20150672A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/558,463 US20130190341A1 (en) 2004-06-04 2012-07-26 High bioavailability opioid formulations
US201361806185P 2013-03-28 2013-03-28

Publications (1)

Publication Number Publication Date
PE20150672A1 true PE20150672A1 (es) 2015-05-21

Family

ID=53487482

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000092A PE20150672A1 (es) 2012-07-26 2013-07-26 Formulaciones de opioides

Country Status (20)

Country Link
US (1) US20240075024A1 (es)
JP (1) JP6417327B2 (es)
CN (1) CN109010255B (es)
AU (3) AU2016244271B2 (es)
CL (1) CL2015000197A1 (es)
CY (1) CY1124016T1 (es)
DK (1) DK2877155T3 (es)
EA (1) EA034855B1 (es)
ES (1) ES2837803T3 (es)
HK (2) HK1205948A1 (es)
HR (1) HRP20210068T1 (es)
HU (1) HUE053273T2 (es)
IL (3) IL296882A (es)
LT (1) LT2877155T (es)
MX (1) MX361873B (es)
MY (1) MY189481A (es)
NZ (2) NZ704012A (es)
PE (1) PE20150672A1 (es)
PT (1) PT2877155T (es)
SG (2) SG10201703964TA (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
WO2019071245A1 (en) * 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. IMPLANTABLE DEPOSITS FOR REGULATED RELEASE OF ANALGESICS TO TREAT POSTHOPERATIVE PAIN ASSOCIATED WITH ORTHOPEDIC SURGERY, AND RELATED DEVICES, SYSTEMS, AND METHODS
WO2020240018A1 (en) * 2019-05-29 2020-12-03 Camurus Ab Administration device & regime
CN117999079A (zh) * 2021-08-20 2024-05-07 苏州恩华生物医药科技有限公司 一种包含塞纳布啡的药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
ATE401054T1 (de) * 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen
DK1845942T3 (da) * 2005-01-14 2014-04-28 Camurus Ab GNRH-analogformuleringer
CA2594710C (en) * 2005-01-14 2011-01-25 Camurus Ab Topical bioadhesive formulations
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
GB2513267B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Also Published As

Publication number Publication date
IL289157A (en) 2022-02-01
PT2877155T (pt) 2020-12-18
SG11201500554XA (en) 2015-02-27
US20240075024A1 (en) 2024-03-07
MY189481A (en) 2022-02-16
ES2837803T3 (es) 2021-07-01
DK2877155T3 (da) 2021-01-18
IL236762A0 (en) 2015-03-31
JP2015522649A (ja) 2015-08-06
AU2016244271A1 (en) 2016-10-27
AU2019200982B2 (en) 2019-07-18
CY1124016T1 (el) 2022-05-27
AU2017279657B2 (en) 2018-11-15
CL2015000197A1 (es) 2015-11-13
LT2877155T (lt) 2021-02-25
HK1205948A1 (en) 2015-12-31
EA201590202A1 (ru) 2015-07-30
EA034855B1 (ru) 2020-03-30
AU2019200982A1 (en) 2019-02-28
MX2015001033A (es) 2015-04-09
JP6417327B2 (ja) 2018-11-07
AU2017279657A1 (en) 2018-01-18
CN109010255B (zh) 2022-10-21
MX361873B (es) 2018-12-18
NZ704012A (en) 2017-09-29
IL296882A (en) 2022-12-01
HRP20210068T1 (hr) 2021-03-05
HK1221636A1 (zh) 2017-06-09
CN109010255A (zh) 2018-12-18
HUE053273T2 (hu) 2021-06-28
NZ735248A (en) 2018-10-26
SG10201703964TA (en) 2017-06-29
AU2016244271B2 (en) 2018-01-18
BR112015001548A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
CO7190238A2 (es) Formulaciones de opioides
DOP2017000261A (es) Derivados de ciclohexano sustituido con amido
PE20151890A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
PE20150668A1 (es) Formulaciones farmaceuticas topicas no acuosas
NZ746271A (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
ECSP13012499A (es) Nuevos compuestos
AR081774A1 (es) Composiciones farmaceuticas de co-cristales de tramadol y coxibs
UY32816A (es) Formulación farmacéutica a base de 1-[2-(2,1,3-benzotiadiazol-5-ilamino)-6(2,6-diclorofenil)-pirido[2,3-d] pirimidin-7-il]-3-tert-butil-uréa
ECSP15013883A (es) Benzamidas
CL2017001024A1 (es) Formulación de buprenorfina inyectable
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
CY1124016T1 (el) Φαρμακοτεχνικες μορφες οπιοειδων
DOP2016000007A (es) Pirazolpiridinas sustituidas
CR20160462A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
PE20150928A1 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
DOP2013000004A (es) Agentes terapeuticos 976
NI201400066A (es) Anillo vaginal que comprende meloxicam y un agente modulador de la libración del principio activo, útil como anticonceptivo de uso continuo en mujeres
CL2015000310A1 (es) Uso de ipidacrina para el tratamiento de los trastornos de potencia, tal como trastornos de la actividad sexual; formulacion farmaceutica que contiene ipidacrina de 3 a 300 mg.
MX360531B (es) Formulación de aroma y fragancia (ii).
MX2015004316A (es) Formulacion de aroma y fragancia (iv).
MX2015004315A (es) Formulacion de aroma y fragancia (vi).
CO7160072A2 (es) Síntesis de compuestos heterocíclicos
CO7131364A2 (es) Anillo vaginal que comprende meloxicam y un agente modulador de la liberación del principio activo, útil como anticonceptivo de uso continuo en mujeres
DOP2014000142A (es) Anillo vaginal que comprende meloxicam y un agente modulador de la liberación del principio activo, útil como anticonceptivo de uso continuo en mujeres

Legal Events

Date Code Title Description
FG Grant, registration